You bought the shares outright???
WOW... that's against my religion. I sold an Oct $10 put for $270.
WOW... that's against my religion. I sold an Oct $10 put for $270.
EXAS April options mis-priced
- Thread starter vanv0029
- Start date
Quote from Landis82:
Don't even think about selling those shares for the rest of the month.
Add on any weakness, if you can. Nice to see you again my friend. Hope life has been treating you well!
I post VERY infrequently on ET.
But I do check my e-mail from time to time.
Hey Wags. Yeah, I haven't seen any posts from you in awhile. I've got limits under the market. I'm about half of size I'd like. Looking for 17-22 after the release. I hope you got that clearing issue resolved.
Someone help me with this as I am now in size in EXAS. What's the value-add to this test over something like this?
http://www.drugstore.com/products/p...=goobase_filler&device=c&network=g&matchtype=
Partially joking, and I understand that this is also a quick methylation test.
http://www.drugstore.com/products/p...=goobase_filler&device=c&network=g&matchtype=
Partially joking, and I understand that this is also a quick methylation test.
The home test and the lab test done when you have your normal checkup
just looks for blood in your stool. It will usually only catch later stage
cancers which have already high mortality rates.
I am not long stock but short puts and long covered calls because I think
the FDA is going to be cautious about approving the EXAS test since it
is the first of the DNA marker tests. DNA market diagnostic tests will
surely be common in the future. So I think the FDA is not going to want to
make any mistake. The current test is just a larger version of a previous test
that had very good results but if there is a few percent lower value anywhere.
Very possible just from mechanics of a new test, stock may not rise much.
The alternative which seems to work better for some types of cancer (not
Colon cancer) is blood DNA tests which could replace the EXAS test.
just looks for blood in your stool. It will usually only catch later stage
cancers which have already high mortality rates.
I am not long stock but short puts and long covered calls because I think
the FDA is going to be cautious about approving the EXAS test since it
is the first of the DNA marker tests. DNA market diagnostic tests will
surely be common in the future. So I think the FDA is not going to want to
make any mistake. The current test is just a larger version of a previous test
that had very good results but if there is a few percent lower value anywhere.
Very possible just from mechanics of a new test, stock may not rise much.
The alternative which seems to work better for some types of cancer (not
Colon cancer) is blood DNA tests which could replace the EXAS test.